(Q27851690)

13 November 2016

title

A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer (English)

1 reference

PubMed

PubMed publication ID

13 November 2016

0 references

0 references

1 reference

1 reference

A Ravaggi

18

0 references

Susan L Neuhausen

25

object named as

S L Neuhausen

0 references

Jeffrey N Weitzel

24

object named as

J N Weitzel

0 references

author name string

E S Ratner

1

0 references

F K Keane

2

0 references

R Lindner

3

0 references

R A Tassi

4

0 references

T Paranjape

5

0 references

M Glasgow

6

0 references

S Nallur

7

0 references

Y Deng

8

0 references

L Lu

9

0 references

L Steele

10

0 references

S Sand

11

0 references

R-U Muller

12

0 references

E Bignotti

13

0 references

S Bellone

14

0 references

M Boeke

15

0 references

X Yao

16

0 references

S Pecorelli

17

0 references

D Katsaros

19

0 references

D Zelterman

20

0 references

M C Cristea

21

0 references

H Yu

22

0 references

T J Rutherford

23

0 references

P E Schwartz

26

0 references

F J Slack

27

0 references

A D Santin

28

0 references

J B Weidhaas

describes a project that uses

29

0 references

language of work or name

English

0 references

publication date

18 October 2012

0 references

published in

Oncogene

0 references

volume

31

0 references

issue

42

0 references

page(s)

4559-66

0 references

limma

1 reference

Europe PubMed Central

22 June 2022

https://europepmc.org/article/PMC/3342446

based on heuristic

inferred from PubMed Central ID database lookup

cites work

A let-7 microRNA-binding site polymorphism in the KRAS 3' UTR is associated with reduced survival in oral cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342446

A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342446

Oncomirs - microRNAs with a role in cancer

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342446

Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342446

MicroRNA signatures in human ovarian cancer

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342446

20 March 2017

Cancer statistics, 2009

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342446

Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342446

A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342446

The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342446

Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342446

A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342446

MicroRNAs in ovarian cancer biology and therapy resistance.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342446

Role of microRNAs in ovarian cancer pathogenesis and potential clinical implications

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342446

Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342446

A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342446

Polymorphisms in microRNA targets: a gold mine for molecular epidemiology

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342446

Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342446

Ovarian cancer: a focus on management of recurrent disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342446

Oncogenic H-Ras up-regulates expression of ERCC1 to protect cells from platinum-based anticancer agents

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342446

Evaluation of survival data and two new rank order statistics arising in its consideration

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342446

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

29 September 2017

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.539

Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.539

Genome-wide transcriptional analysis of carboplatin response in chemosensitive and chemoresistant ovarian cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.539

Evaluation of Kras gene mutation and copy number gain in non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.539

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.539

Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.539

MicroRNA let-7a: a potential marker for selection of paclitaxel in ovarian cancer management

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.539

miRNAs in the spotlight: Making 'silent' mutations speak up

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.539

Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.539

31 March 2020

Identifiers

DOI

10.1038/ONC.2011.539

1 reference

Dimensions Publication ID

1000308252

0 references

1 reference

1 reference

PubMed publication ID

22139083

1 reference